Sagimet Biosciences (SGMT) Retained Earnings (2022 - 2026)

Sagimet Biosciences' Retained Earnings history runs 5 years deep, the most recent figure standing at $459.4 million for Q1 2026.

• On a quarterly basis, Retained Earnings rose 1.57% year-over-year to $459.4 million in Q1 2026; TTM through Mar 2026 was $459.4 million, a 1.57% increase from a year earlier, with the FY2025 full-year figure at $120000.0, down 47.83% from the prior year.
• Retained Earnings grew to $459.4 million in Q1 2026 per SGMT's latest filing, from $120000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $459.4 million in Q1 2026 and bottomed at -$279.1 million in Q3 2024.
• The 5-year median for Retained Earnings is $117000.0 (2025), against an average of -$23.6 million.
• Across the five-year window, Retained Earnings sank 818.24% in 2024 and soared 276.43% in 2025, its largest moves.
• Year by year, Retained Earnings stood at $35.0 million in 2022, then tumbled by 813.53% to -$249.7 million in 2023, then jumped by 100.09% to $230000.0 in 2024, then sank by 47.83% to $120000.0 in 2025, then soared by 382771.67% to $459.4 million in 2026.
• Per Business Quant, the three latest SGMT Retained Earnings figures stand at $459.4 million (Q1 2026), $120000.0 (Q4 2025), and $117000.0 (Q3 2025).